尽管新疗法取得了进展，但老年急性淋巴细胞白血病 (ALL) 患者的治疗仍然是一个未得到满足的医疗需求。随着年龄的增长，与年轻患者相比，ALL患者的CR率显着降低，早期死亡率和复发率更高，生存率更差。这是由于老年人中不良预后因素的发生率较高以及对化疗的耐受性降低。在针对老年患者 Ph/BCR-ABL (Ph) 阴性 ALL 制定中等强度化疗方案方面已取得进展，最近的 II 期研究已探索将免疫疗法纳入初始治疗，并取得了非常有希望的结果。然而，为该年龄组建立新的标准治疗方案和改进一般管理策略仍然是一项悬而未决的任务。版权所有 © 2024 美国血液学会。

Despite advancements in new treatments, management of older patients with acute lymphoblastic leukaemia (ALL) remains an unmet medical need. With increasing age, ALL patients have a significantly lower CR rate, higher early mortality and relapse rate, and poorer survival compared to younger patients. This is attributed to a higher prevalence of adverse prognostic factors among older individuals and reduced tolerance to chemotherapy. Progress has been made in tailoring moderately intensive chemotherapy protocols for Ph/BCR-ABL (Ph) negative ALL in older patients, and recent phase II studies have explored integrating immunotherapy into initial treatment with very promising results. However, establishing new standard regimens for this age group remains and improving general management strategy is a pending task.Copyright © 2024 American Society of Hematology.